STAA - STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery.
As of May 15, 2026: spot at $32.44, ATM IV 47.4%, max pain $20.00, net GEX $594.6K.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Market Cap
- $1.46B
- Beta
- 1.20
- 52-Week Range
- 15.59-30.81
- CEO
- Warren Foust
- Employees
- 1,157
- IPO Date
- Feb 24, 1992
- Exchange
- NASDAQ
What STAA Looks Like to Options Traders Today
IV rank of 27.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($594.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.055) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The STAA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked STAA overview questions
- What is STAA?
- STAA is the ticker symbol for STAAR Surgical Company, a listed security. STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. Listed on NASDAQ. STAA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the STAA options snapshot look like today?
- As of May 15, 2026, the STAA options snapshot shows spot at $32.44, ATM IV 47.4%, IV rank 27.8%, max pain $20.00, net GEX $594.6K, expected move 13.59%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are STAA's key statistics?
- STAAR Surgical Company (STAA) carries a market capitalization of $1.46B, beta of 1.20 relative to the broader market, 52-week range of 15.59-30.81. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does STAA belong to?
- STAAR Surgical Company operates in the Healthcare sector, in the Medical - Instruments & Supplies industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare STAA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the STAA data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).